Table 1.
Summary of AEs, SAEs, AESIs, and ADRs reported in patients receiving R-chemo
| Baseline characteristics | AE (any grade), n (%) | AE (grade 3–4), n (%) | SAE, n (%) | AESI, n (%) | ADR, n (%) | |
|---|---|---|---|---|---|---|
| Total (n = 279) | 267(95.7) | 147(52.7) | 47(16.8) | 46 (16.5) | 226 (81.0) | |
| Age, y | 19–60 (n = 160) | 206 (95.8) | 103 (47.9) | 30 (14.0) | 32 (14.9) | 172 (80.0) |
| 61–80 (n = 109) | 22 (95.7) | 16 (69.6) | 7(30.4) | 6 (26.1) | 21(91.3) | |
| ≤18 to >80 (n = 10) | 42 (95.5) | 30 (68.2) | 11(25.0) | 9 (20.5) | 36 (81.8) | |
| History of diseases | Heart diseases (n = 23) | 10 (100.0) | 5 (50.0) | 3 (30.0) | 2 (20.0) | 10 (100.0) |
| Liver diseases (n = 44) | 152 (95.0) | 76 (47.5) | 22 (13.8) | 22 (13.8) | 126 (78.8) | |
| No heart or liver diseases (n = 215) | 105 (96.3) | 66 (60.6) | 22 (20.2) | 22 (20.2) | 90 (82.6) | |
ADR adverse drug reaction, AE adverse event, AESI adverse event of special interest, chemo chemotherapy, SAE severe adverse event, R rituximab, y year